Homocysteine and metabolic syndrome: From clustering to additional utility in prediction of coronary heart disease

Journal of Cardiology

Volumn 64, Issue 4, 2014, Pages 290-296

  Esteghamati, Alireza ^a   Hafezi Nejad, Nima ^a   Zandieh, Ali ^a   Sheikhbahaei, Sara ^a   Ebadi, Maryam ^a   Nakhjavani, Manouchehr ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biomarkers; Clinical utility; Coronary heart disease; Homocysteine; Metabolic syndrome

Indexed keywords

HOMOCYSTEINE; BIOLOGICAL MARKER;

ABDOMINAL OBESITY; ADULT; ANGINA PECTORIS; ARTICLE; DIABETES MELLITUS; ELEVATED BLOOD PRESSURE; ENTROPY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD; CORONARY ARTERY DISEASE; RISK ASSESSMENT;

ADULT; BIOLOGICAL MARKERS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84926245459     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.02.001     Document Type: Article

References (57)

1. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., Abraham J., Adair T., Aggarwal R., Ahn S.Y., Alvarado M., Anderson H.R., Anderson L.M., Andrews K.G., Atkinson C., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
2. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., Bravata D.M., Dai S., Ford E.S., Fox C.S., Franco S., Fullerton H.J., Gillespie C., Hailpern S.M., Heit J.A., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2012, 127:e6-e245.
3. Ebrahim S., Taylor F., Ward K., Beswick A., Burke M., Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2011, CD001561.
4. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., May M., Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007, 335:136.
5. Wilson P.W., D'Agostino R., Bhatt D.L., Eagle K., Pencina M.J., Smith S.C., Alberts M.J., Dallongeville J., Goto S., Hirsch A.T., Liau C.S., Ohman E.M., Röther J., Reid C., Mas J.L., et al. An international model to predict recurrent cardiovascular disease. Am J Med 2012, 125:695-703.e1.
6. Yeboah J., McClelland R.L., Polonsky T.S., Burke G.L., Sibley C.T., O'Leary D., Carr J.J., Goff D.C., Greenland P., Herrington D.M. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012, 308:788-795.
7. Helfand M., Buckley D.I., Freeman M., Fu R., Rogers K., Fleming C., Humphrey L.L. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 151:496-507.
8. Wang T.J., Wollert K.C., Larson M.G., Coglianese E., McCabe E.L., Cheng S., Ho J.E., Fradley M.G., Ghorbani A., Xanthakis V., Kempf T., Benjamin E.J., Levy D., Vasan R.S., Januzzi J.L. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012, 126:1596-1604.
9. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh C., Jacques P.F., Rifai N., Selhub J., Robins S.J., Benjamin E.J., D'Agostino R.B., Vasan R.S. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
10. Hayden M.R., Tyagi S.C. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J 2004, 3:4.
11. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042-1050.
12. Esteghamati A., Zandieh A., Khalilzadeh O., Meysamie A., Ashraf H. Clustering of metabolic syndrome components in a Middle Eastern diabetic and non-diabetic population. Diabetol Metab Syndr 2010, 2:36.
13. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., Williams G.R. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250.
14. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., Isles C., Macfarlane P.W., Packard C.J., Cobbe S.M., Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.
15. Qin X., Huo Y., Xie D., Hou F., Xu X., Wang X. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Clin Nutr 2013, 32:722-727.
16. Huang T., Chen Y., Yang B., Yang J., Wahlqvist M.L., Li D. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin Nutr 2012, 31:448-454.
17. Vaya A., Carmona P., Badia N., Perez R., Hernandez Mijares A., Corella D. Homocysteine levels and the metabolic syndrome in a Mediterranean population: a case-control study. Clin Hemorheol Microcirc 2011, 47:59-66.
18. Godsland I.F., Rosankiewicz J.R., Proudler A.J., Johnston D.G. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab 2001, 86:719-723.
19. Hajer G.R., van der Graaf Y., Olijhoek J.K., Verhaar M.C., Visseren F.L. Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. Heart 2007, 93:216-220.
20. Esteghamati A., Abbasi M., Nakhjavani M., Yousefizadeh A., Basa A.P., Afshar H. Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovasc Diabetol 2006, 5:15.
21. Esteghamati A., Ashraf H., Rashidi A., Meysamie A. Waist circumference cut-off points for the diagnosis of metabolic syndrome in Iranian adults. Diabetes Res Clin Pract 2008, 82:104-107.
22. Nakhjavani M., Morteza A., Jenab Y., Ghaneei A., Esteghamati A., Karimi M., Farokhian A. Gender difference in albuminuria and ischemic heart disease in type 2 diabetes. Clin Med Res 2012, 10:51-56.
23. Ives D.G., Fitzpatrick A.L., Bild D.E., Psaty B.M., Kuller L.H., Crowley P.M., Cruise R.G., Theroux S. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995, 5:278-285.
24. Sacks D.B., Arnold M., Bakris G.L., Bruns D.E., Horvath A.R., Kirkman M.S., Lernmark A., Metzger B.E., Nathan D.M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011, 34:e61-e99. National Academy of Clinical Biochemistry; Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry.
25. Wijndaele K., Beunen G., Duvigneaud N., Matton L., Duquet W., Thomis M., Lefevre J., Philippaerts R.M. A continuous metabolic syndrome risk score: utility for epidemiological analyses. Diabetes Care 2006, 29:2329.
26. Pencina M.J., D'Agostino R.B., Larson M.G., Massaro J.M., Vasan R.S. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 2009, 119:3078-3084.
27. Steyerberg E.W., Van Calster B., Pencina M.J. Performance measures for prediction models and markers: evaluation of predictions and classifications. Rev Esp Cardiol 2011, 64:788-794.
28. Pencina M.J., D'Agostino R.B., Vasan R.S. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010, 48:1703-1711.
29. Veeranna V., Zalawadiya S.K., Niraj A., Pradhan J., Ference B., Burack R.C., Jacob S., Afonso L. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011, 58:1025-1033.
30. Sun Y., Chien K.L., Hsu H.C., Su T.C., Chen M.F., Lee Y.T. Use of serum homocysteine to predict stroke, coronary heart disease and death in ethnic Chinese. 12-year prospective cohort study. Circ J 2009, 73:1423-1430.
31. Chambers J.C., Obeid O.A., Refsum H., Ueland P., Hackett D., Hooper J., Turner R.M., Thompson S.G., Kooner J.S. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000, 355:523-527.
32. de Bree A., Verschuren W.M., Blom H.J., Nadeau M., Trijbels F.J., Kromhout D. Coronary heart disease mortality, plasma homocysteine, and B-vitamins: a prospective study. Atherosclerosis 2003, 166:369-377.
33. Troughton J.A., Woodside J.V., Young I.S., Arveiler D., Amouyel P., Ferrieres J., Ducimetière P., Patterson C.C., Kee F., Yarnell J.W., Evans A. Homocysteine and coronary heart disease risk in the PRIME study. Atherosclerosis 2007, 191:90-97. PRIME Study Group.
34. Al-Nozah M., Al-Daghri N., Bartlett W.A., Al-Attas O., Al-Maatouq M., Martin S.C., Kumar S., Jones A.F. Serum homocysteine concentration is related to diabetes mellitus, but not to coronary heart disease, in Saudi Arabians. Diabetes Obes Metab 2002, 4:118-123.
35. Humphrey L.L., Fu R., Rogers K., Freeman M., Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008, 83:1203-1212.
36. Hoogeveen E.K., Kostense P.J., Jakobs C., Dekker J.M., Nijpels G., Heine R.J., Bouter L.M., Stehouwer C.D. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000, 101:1506-1511.
37. Steyerberg E.W., Vickers A.J., Cook N.R., Gerds T., Gonen M., Obuchowski N., Pencina M.J., Kattan M.W. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2009, 21:128-138.
38. De Bree A., Verschuren W.M., Kromhout D., Kluijtmans L.A., Blom H.J. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002, 54:599-618.
39. Hellgren M., Melander A., Ostgren C.J., Rastam L., Lindblad U. Inverse association between plasma homocysteine, sulphonylurea exposure and physical activity: a community-based sample of type 2 diabetes patients in the Skaraborg Hypertension and Diabetes Project. Diabetes Obes Metab 2005, 7:421-429.
40. Fonseca V., Keebler M., Dicker-Brown A., Desouza C., Poirier L.A., Murthy S.N., McNamara D.B. The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. Metabolism 2002, 51:783-786.
41. Setola E., Monti L.D., Galluccio E., Palloshi A., Fragasso G., Paroni R., Magni F., Sandoli E.P., Lucotti P., Costa S., Fermo I., Galli-Kienle M., Origgi A., Margonato A., Piatti P. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 2004, 151:483-489.
42. Meigs J.B., Jacques P.F., Selhub J., Singer D.E., Nathan D.M., Rifai N., D'Agostino R.B., Wilson P.W. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes Care 2001, 24:1403-1410. Framingham Offspring Study.
43. Rhee E.J., Hwang S.T., Lee W.Y., Yoon J.H., Kim B.J., Kim B.S., Kang J.H., Lee M.H., Park J.R., Sung K.C. Relationship between metabolic syndrome categorized by newly recommended by International Diabetes Federation criteria with plasma homocysteine concentration. Endocr J 2007, 54:995-1002.
44. Rosolova H., Simon J., Mayer O., Racek J., Dierze T., Jacobsen D.W. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. Physiol Res 2002, 51:93-98.
45. Guven A., Inanc F., Kilinc M., Ekerbicer H. Plasma homocysteine and lipoprotein (a) levels in Turkish patients with metabolic syndrome. Heart Vessels 2005, 20:290-295.
46. Neugebauer S., Tarnow L., Stehouwer C., Teerlink T., Baba T., Watanabe T., Parving H.H. Total plasma homocysteine is associated with hypertension in Type I diabetic patients. Diabetologia 2002, 45:1315-1324.
47. Vaya A., Rivera L., Hernandez-Mijares A., de la Fuente M., Sola E., Romagnoli M., Alis R., Laiz B. Homocysteine levels in morbidly obese patients: its association with waist circumference and insulin resistance. Clin Hemorheol Microcirc 2012, 52:49-56.
48. Forouhi N.G., Sattar N. CVD risk factors and ethnicity-a homogeneous relationship. Atheroscler Suppl 2006, 7:11-19.
49. Esteghamati A., Abbasi M., Rashidi A., Meysamie A., Khalilzadeh O., Haghazali M., Asgari F., Nakhjavani M. Optimal waist circumference cut-offs for the diagnosis of metabolic syndrome in Iranian adults: results of the Third National Survey of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007). Diabet Med 2009, 26:745-746.
50. Giles W.H., Croft J.B., Greenlund K.J., Ford E.S., Kittner S.J. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey. Am Heart J 2000, 139:446-453.
51. Kasiman K., Eikelboom J.W., Hankey G.J., Lee S.P., Lim J.P., Lee J.H., Chang H.M., Wong M.C., Chen C.P. Ethnicity does not affect the homocysteine-lowering effect of B-vitamin therapy in Singaporean stroke patients. Stroke 2009, 40:2209-2211.
52. Sosin M.D., Patel J.V., Bhatia G.S., Hughes E.A., Davis R.C., Lip G.Y. Effects of white European, African Caribbean and South Asian ethnicity on homocysteine levels in patients with systolic heart failure. Int J Cardiol 2008, 129:69-75.
53. Albert M.A., Glynn R.J., Buring J.E., Ridker P.M. Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol 2007, 99:1246-1251.
54. Wijeyaratne C.N., Nirantharakumar K., Balen A.H., Barth J.H., Sheriff R., Belchetz P.E. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?. Clin Endocrinol 2004, 60:560-567.
55. Rachas A., Raffaitin C., Barberger-Gateau P., Helmer C., Ritchie K., Tzourio C., Amouyel P., Ducimetière P., Empana J.P. Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study. Heart 2012, 98:650-655.
56. Kullo I.J., Li G., Bielak L.F., Bailey K.R., Sheedy P.F., Peyser P.A., Turner S.T., Kardia S.L. Association of plasma homocysteine with coronary artery calcification in different categories of coronary heart disease risk. Mayo Clin Proc 2006, 81:177-182.
57. Hughes M.F., Saarela O., Stritzke J., Kee F., Silander K., Klopp N., Kontto J., Karvanen J., Willenborg C., Salomaa V., Virtamo J., Amouyel P., Arveiler D., Ferrières J., Wiklund P.G., et al. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS ONE 2012, 7:e40922.